Navigation Links
First targeted nanomedicine to enter human clinical studies
Date:4/4/2012

ting drug encapsulated nanoparticles directly to the site of tumors. This leads to substantially better efficacy and safety.

In the study, the researchers produced data that include pharmacokinetic characteristics consistent with prolonged circulation and controlled drug release with plasma concentrations remaining up to at least 100-fold higher than conventional docetaxel for over 24 hours, as well as up to a 10-fold increase in intratumoral drug concentrations with prolonged and enhanced tumor growth suppression in multiple tumor models compared with conventional docetaxel.

Moreover, initial clinical data in a heavily pretreated patient population with 17 patients with advanced or metastatic solid tumor cancers indicated that BIND-014 displays pharmacological characteristics consistent with preclinical findings of differentiated pharmacokinetics and accumulation at tumor sites with clinical effects seen at doses as low as 20 percent of the normally prescribed docetaxel dose and in cancers in which docetaxel has minimal activity (e.g., cervical cancer).

"The development of BIND-014 demonstrates that drug properties such as solubility, metabolism, plasma binding, biodistribution and target tissue accumulation will no longer be constrained to the same extent by the drug chemical composition. It will also become the function of the physicochemical properties of nanoparticles. This will allow for an unprecedented ability to make better medicines for our patients as demonstrated by our emerging clinical data." said Farokhzad.

The researchers note that while the science and technology of BIND-014 builds upon docetaxel's mechanism of action, the emerging evidence is that BIND-014 significantly changes the biological effects of docetaxel by virtue of fundamental changes in pharmacology including major increases in tumor concentration.

To date, the researchers note that BIND-014 has been administered at doses of up to 75 mg/
'/>"/>

Contact: Marjorie Montemayor-Quellenberg
mmontemayor-quellenberg@partners.org
617-534-2208
Brigham and Women's Hospital
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. First Bedside Gene Test Shows Promise
2. Complications in patients undergoing PCI tend to occur within first 30 days
3. $4.2 million grant helps plan, launch first Alzheimers prevention trials
4. First national guideline for sudden hearing loss published
5. Researchers develop first theranostic treatment for acute lymphoblastic leukemia (ALL)
6. First study of its kind finds no increased risk of heart disease for kidney donors
7. UC San Diego among first in nation to treat brain cancer with novel viral vector
8. First breakdown of public health data for Cleveland neighborhoods
9. Rapid Flu Tests a Good First Step: Study
10. First study on long-term cognitive effects of breast cancer chemotherapy finds subtle impairment among women who received CMF regimen
11. Mount Sinai first to use visually guided catheter ablation system to treat AFib patient
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... (May 18, 2013) A ground-breaking advance in ... according to research presented today at Digestive Disease ... minimal withdrawal time for colonoscopies and exploring safer ... colonoscopy, doctors use a device called a colonoscope ... colorectal cancer allows a doctor to look for ...
(Date:5/18/2013)... York (PRWEB) May 18, 2013 ... mesh products continue to move forward in a consolidated ... Bernstein Liebhard LLP reports. According to a notice on ... the Ethicon pelvic mesh litigation will be held on ... complaints have been filed in the proceeding on behalf ...
(Date:5/18/2013)... HealthDay Reporter , , FRIDAY, May 17 (HealthDay News) -- It ... but new research shows that college women are more likely ... than are college men. Much of this difference ... on a weekly basis is much lower for women than ... for men. But, there,s good reason for that difference. Women ...
(Date:5/18/2013)... After working diligently for months and putting in a ... integration of the fitment specs for the redesigned 2012 Hyundai ... the automobile market with its extraordinary features and unique combination ... the latest entry in the size it up ... year 2013. , Aptly suiting its name, 2012 Hyundai ...
(Date:5/18/2013)... DC (PRWEB) May 18, 2013 Family Magazine ... designation for excellence by Follow Media Consulting, Inc. in the ... signifies the continued commitment and dedication of the areas best ... , No one knows parenting better than Brenda Hyde, a ... is to help parents know about the vast resources available ...
Breaking Medicine News(10 mins):Health News:New colonoscope provides ground-breaking view of colon 2Health News:New colonoscope provides ground-breaking view of colon 3Health News:New colonoscope provides ground-breaking view of colon 4Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 2Health News:Transvaginal Mesh Lawsuits: Bernstein Liebhard LLP Notes Upcoming Case Management Conference in New Jersey Ethicon Pelvic Mesh Litigation 3Health News:College Women More Prone to Problem Drinking Than Men: Study 2Health News:College Women More Prone to Problem Drinking Than Men: Study 3Health News:Renowned Rim Fitments Provider SizeItUp Launched Database Integrations for the 2012 Hyundai Genesis 2Health News:Summer Camps in DC "Best of the Best" Awarded to Family Magazine of Washington DC for Excellence by Follow Media Consulting, Inc. 2
... -- Alcohol use by American teens has dropped to historic ... believe it,s a dangerous drug, according to an annual national ... and the University of Michigan. The nationally representative survey ... 400 public and private schools found a continuing trend of ...
... GURGAON, Delhi (NCR), India -- Vishwa Mohan Katoch, M.D., ... India: Future Directions" at the AACR International Conference on ... Therapy, Dec. 13-16, 2011, in Gurgaon, Delhi (NCR), India. ... India Department of Health Research and director-general of the ...
... cancers worldwide. Kaposi,s sarcoma herpesvirus (KSHV) is an etiological ... lymphoproliferative malignancies. KS is the most common cancer in ... cancer deaths in many subequatorial African countries as a ... of Biotechnology and Research Programs Unit (Genome-Scale Biology) at ...
... and the Management Sciences (INFORMS) today announced the award ... Medal to Dr. Don N. Kleinmuntz, President and co-founder ... web-based financial analytics and performance management software tools used ... their financial planning, budgeting, and reporting processes. , ...
... News) --,A new study finds that two out of ... hands. Researchers gave seven scenarios to 85 third-year ... asked them to identify which of the situations required ... correctly identified the five scenarios that required hand hygiene: ...
... conducted by researchers at Boston University School of Medicine ... house dust extract (HDE) causes pulmonary inflammation that aggravates ... PhD, professor of pathology, was published in the December ... and was selected by the editorial board as the ...
Cached Medicine News:Health News:Alcohol Use Down, Pot Use Up Among U.S. Teens 2Health News:KS-herpesvirus induces reprogramming of lymphatic endothelial cells to invasive mesenchymal cells 2Health News:INFORMS presents Ramsey Medal to health care financial analytics executive Don Kleinmuntz 2
(Date:5/17/2013)... 2013  Boehringer Ingelheim will contribute to advancing ... American Thoracic Society International Conference (ATS 2013) in ... – 22. Data will highlight research ... of chronic obstructive pulmonary disease (COPD) [Spiriva® HandiHaler® ... compounds for asthma, idiopathic pulmonary fibrosis (IPF) and ...
(Date:5/17/2013)... 2013 Oramed Pharmaceuticals Inc. (NASDAQCM: ... delivery systems, announced today that the United States Food ... New Drug application(IND) for ORMD-0801, its oral insulin capsule. ... FDA clearance to proceed," stated Nadav Kidron ... a major milestone for Oramed and we look forward ...
(Date:5/16/2013)... CHICAGO, Ill. and MECHELEN, Belgium ... (Euronext: GLPG) and AbbVie (NYSE: ABBV ) ... collaboration to include Crohn,s disease.  Galapagos will fund and ... is designed to facilitate rapid progression into Phase 3.  ... 2015, AbbVie will pay Galapagos $50 million.  The terms ...
Breaking Medicine Technology:Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 2Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S. 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6
... couples to create page on Pinktimeline.com to receive £50 ... have launched a fundraising resource on their website, http://www.pinktimeline.com ... for associated costs. Couples can create a private fundraising page ... raise funds for specialty consultations, fertility treatments or even to ...
... 25, 2011 INNOPHARMA LLC announced today FDA approval of ... generic equivalent of Zyprexa® injection). As the developer ... with Sandoz Inc., pursuant to which Sandoz will sell, market ... About INNOPHARMA: INNOPHARMA is ...
Cached Medicine Technology:First Response Launches IVF Fundraising Resource for Those Trying for a Baby 2First Response Launches IVF Fundraising Resource for Those Trying for a Baby 3
... objective and high power negative lens delivering ... true benefit of this system is ease ... is made possible due to a superior ... bar and individual interpupillary adjustment provides stability ...
... 23 gauge thin wall irrigation. 25 ... degree shaft 10 mm from tip ... mm behind aspiration tip. Side taper ... (18.1 inches) of silicone tubing (N5941 ...
... with five legs for extra stability. Adjustable ... vertical travel 6"). 2" ball bearing swivel ... retardant upholstery, available in black vinyl as ... Top of the range pneumatic stool with ...
Lacrimal Cannulas, 26 g. curved. Overall length 29 mm. 5/box....
Medicine Products: